Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities

Core Points - The United States District Court for the District of Massachusetts has approved a proposed class action settlement for purchasers of AlloVir, Inc. securities, amounting to $1,000,000 [2][3] Group 1: Settlement Details - The settlement benefits individuals or entities who purchased AlloVir securities from January 11, 2023, to December 21, 2023 [1] - The proposed settlement includes a hearing scheduled for July 30, 2025, to determine its fairness and adequacy [3] - Lead Counsel may request attorneys' fees of up to 33.33% of the settlement fund and reimbursement of litigation expenses up to $100,000 [3] Group 2: Claim Process - Settlement Class Members must submit a Claim Form by August 19, 2025, to be eligible for distribution from the Net Settlement Fund [6] - Instructions for submitting the Claim Form and obtaining transaction data from brokerages are available on the case website [6] - Members wishing to exclude themselves from the Settlement Class must submit a written request by July 9, 2025 [7] Group 3: Objections and Inquiries - Any objections to the proposed settlement or related motions must be filed with the Court by July 9, 2025 [8] - Inquiries regarding the settlement can be directed to Lead Counsel or the Claims Administrator [5][6]